Compare BioNano Genomics Inc (BNGO) vs Orion Office REIT Inc (ONL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Orion Office REIT Inc — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.66M), while Orion Office REIT Inc trades at $2.78 (market cap $158.01M). The key difference: Orion Office REIT Inc is far larger — about 11.6× BioNano Genomics Inc's market cap, and Orion Office REIT Inc pays a 2.89% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | ONL | |
|---|---|---|
Market Cap | $13.66M | $158.01M |
Sector | Health | Real Estate |
52-Week High | $4.92 | $3.04 |
52-Week Low | $1.06 | $1.93 |
Enterprise Value | $16.26M | $574.95M |
Dividend Yield | — | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.
The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.
ONL trades at $2.83, up 2.91% with a bullish technical signal and strong moving average support. The company reported mixed Q2 2026 results with an EPS beat but continues to face fundamental challenges including declining revenue from $208M in 2022 to $148M in 2025 and negative net margins. Recent news highlights strategic review progress and portfolio repositioning efforts.
The outlook remains cautious despite technical strength. While the stock shows bullish momentum and pays consistent dividends, persistent revenue declines, negative profitability metrics, and high debt levels pose significant risks. Analyst sentiment is evenly split between Buy and Hold recommendations, reflecting uncertainty about the company's turnaround strategy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Orion Office REIT Inc
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.
Read more on ONL →
